Delivery Order SPE2DB24D2205-SPE2DB25FEGKT
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $2,108.70. This competitively awarded, non-set-aside contract represents a firm fixed price delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The place of performance is...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,537.84 firm fixed price delivery order on July 29, 2025, for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of July 30, 2025. This non-competitive delivery order was placed against AmerisourceBergen's existing indefinite delivery contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and running through December 2026. The product will be delivered to the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $1,405.80. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 5, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a non-set-aside procurement, reflecting the company's...
- The Defense Logistics Agency awarded a $2,661.40 delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This contract represents a competitive, non-set-aside award under a firm fixed-price arrangement with an ultimate completion date of August 18, 2025. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, valued at $1,150.32. This is a firm fixed price delivery order with an ultimate completion date of July 28, 2025, and represents a non-set-aside competitive award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $1,054.35. This is a firm fixed price, non-set-aside delivery order executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December 2026. The performance...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, valued at $1,514.61, with an ultimate completion date of July 31, 2025. This non-competitive delivery order represents a firm fixed price pharmaceutical supply transaction, with performance based in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The award was issued on July 30, 2025, as part of AmerisourceBergen's...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $15,182.64 on August 15, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This competitively awarded, firm fixed-price delivery order is not set-aside and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania, with an ultimate completion date of August 18, 2025. The award represents a small transaction within AmerisourceBergen's extensive pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,903.58 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This contract, issued on August 11, 2025, with an ultimate completion date of August 12, 2025, represents a firm fixed-price procurement with no set-aside designation, indicating the award was made through open competition. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order valued at $1,779.30 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This competitive award, issued on August 7, 2025, with an ultimate completion date of August 8, 2025, represents a firm fixed-price transaction with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, reflecting the company's role as a major...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB25FEGKTDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $5,984.98 to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. The contract represents a firm fixed price delivery order with an ultimate completion date of August 19, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation, reflecting AmerisourceBergen's demonstrated capability to meet federal pharmaceutical procurement requirements through open competition. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 through December 2026. As a critical pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen supplies a comprehensive range of medical products to support military and veteran healthcare systems, including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. The current award supports the Defense Health Agency and related government healthcare systems with essential diabetes management pharmaceuticals as part of the company's extensive portfolio of federal medical supply deliveries.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.0k | 8/18/25 |